Journal article Open Access

DESIGN & MOLECULAR DOCKING STUDIES OF COUMARIN SUBSTITUTED 1, 3, 4-OXADIAZOLES AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS.

Purohit S.S.*, Kulkarni V.H., Joshi S.D.


DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.5281/zenodo.3864857</identifier>
  <creators>
    <creator>
      <creatorName>Purohit S.S.*, Kulkarni V.H., Joshi S.D.</creatorName>
      <affiliation>S.E.T.'s College of Pharmacy, S. R. Nagar, Near Microwave Tower, Dharwad-580002.</affiliation>
    </creator>
  </creators>
  <titles>
    <title>DESIGN &amp; MOLECULAR DOCKING STUDIES OF COUMARIN SUBSTITUTED 1, 3, 4-OXADIAZOLES AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS.</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2020</publicationYear>
  <subjects>
    <subject>GSK-3 Inhibitors, Coumarin Containing 1,3, 4-Oxadiazoles, Design &amp; Molecular Docking.</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2020-05-29</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/3864857</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.5281/zenodo.3864856</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/iajpr</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;Glycogen synthase kinase 3 (GSK-3) is a &lt;a href="http://en.wikipedia.org/wiki/Serine/threonine_protein_kinase"&gt;serine/threonine protein kinase&lt;/a&gt; that mediates the addition of phosphate molecules onto &lt;a href="http://en.wikipedia.org/wiki/Serine"&gt;serine&lt;/a&gt; and &lt;a href="http://en.wikipedia.org/wiki/Threonine"&gt;threonine&lt;/a&gt; amino acid residues. First discovered in 1980 as a regulatory kinase for its namesake, &lt;a href="http://en.wikipedia.org/wiki/Glycogen_synthase"&gt;Glycogen synthase&lt;/a&gt;, GSK-3 has since been identified as a kinase for over forty different proteins in a variety of different pathways. GSK-3 has recently been the subject of much research because it has been implicated in a number of diseases, including Type II diabetes (&lt;a href="http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2"&gt;Diabetes mellitus type 2&lt;/a&gt;), &lt;a href="http://en.wikipedia.org/wiki/Alzheimer%27s_Disease"&gt;Alzheimer&amp;#39;s Disease&lt;/a&gt;, &lt;a href="http://en.wikipedia.org/wiki/Inflammation"&gt;inflammation&lt;/a&gt;, &lt;a href="http://en.wikipedia.org/wiki/Cancer"&gt;cancer&lt;/a&gt;, and &lt;a href="http://en.wikipedia.org/wiki/Bipolar_disorder"&gt;bipolar disorder&lt;/a&gt;. A plethora of GSK-3 inhibitors has been described and most of the effects were observed in vitro and cellular studies. Present study is aimed at design of GSK-3 Inhibitors, their molecular docking studies using online molecular docking software, i.e. www. Dockingserver.com. Based upon previous studies on 1, 3, 4-oxadiazoles as GSK-3 inhibitors, 1, 3, 4-oxadiazole molecule skeleton was taken as the core skeleton &amp;amp; 4 different modifications were made. The compounds were docked with GSK (PDB ID: 3f88 and PDB ID: 4E7W).The results have shown appreciable molecular docking interactions with the GSK-3 protein amino acid residues. The Est. inhibition constant, Ki values for the ligands were observed in &amp;micro;M values. . It is observed that Ligand I has shown Est. free energy of binding -10.17 which is said to be better than the other 3 ligands &amp;amp; reference ligands.&lt;/p&gt;</description>
  </descriptions>
</resource>
50
24
views
downloads
All versions This version
Views 5050
Downloads 2424
Data volume 38.1 MB38.1 MB
Unique views 4141
Unique downloads 2222

Share

Cite as